USFDAMay 14, 2026, 05:32 PM
Glucotrack Submits IDE to FDA for CBGM; Reports Q1 Net Loss $4.33M
AI Summary
Glucotrack, Inc. submitted an Investigational Device Exemption (IDE) application to the U.S. FDA for a U.S. clinical study of its implantable continuous blood glucose monitor (CBGM) technology, marking a significant regulatory milestone. For the first quarter of 2026, the company reported a net loss of $4.33 million, an improvement from $6.83 million in Q1 2025. However, cash and cash equivalents decreased to $3.93 million from $7.38 million at year-end 2025, and management raised substantial doubt about the company's ability to continue as a going concern due to accumulated deficits and negative cash flow.
Key Highlights
- Submitted Investigational Device Exemption (IDE) application to U.S. FDA for CBGM clinical study.
- Reported Q1 2026 net loss of $4.33 million, an improvement from $6.83 million in Q1 2025.
- Cash and cash equivalents decreased to $3.93 million as of March 31, 2026, from $7.38 million.
- Total operating expenses increased to $4.20 million in Q1 2026 from $3.50 million in Q1 2025.
- Net cash used in operating activities increased to $4.05 million from $2.94 million year-over-year.
- Management raised substantial doubt about the company's ability to continue as a going concern.
- Accumulated deficit reached $156.17 million as of March 31, 2026.
- Raised $591 thousand from equity sales (ELOC and pre-funded warrants) in Q1 2026.
Price Impact
More from GCTK